Generally, yes. GLP-1 receptor agonists are peptides cleared by peptidases, not CYP450 enzymes, so no clinically significant interaction is expected with modern regimens like Biktarvy — the Liverpool checker rates semaglutide and tirzepatide with BIC/FTC/TAF as “No Interaction Expected”[3]. The federal ARV guidelines advise prescribing GLP-1s in people with HIV per general-population indications[1]. Coordinate with your HIV provider first.
The drugs, and why the pharmacology is reassuring
The class in question: semaglutide (Ozempic and Rybelsus for type 2 diabetes, Wegovy for weight management), tirzepatide (Mounjaro for diabetes, Zepbound for weight — technically a dual GLP-1/GIP agonist), liraglutide (Victoza, Saxenda), and dulaglutide (Trulicity)[12]. FDA has approved semaglutide 2.4 mg weekly for chronic weight management in adults with obesity, or overweight plus a weight-related condition[9].
The interaction picture rests on how these molecules are cleared. The Liverpool HIV Drug Interactions database states semaglutide “is metabolized by the enzyme neutral endopeptidase” and tirzepatide “is metabolized by proteolytic cleavage” — peptide pathways, not the CYP450 system that drives most antiretroviral interactions[2][3]. Liverpool's verdict for semaglutide with FTC/TAF and for tirzepatide with BIC/FTC/TAF is the same: “Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely”[2][3]. Worth saying plainly: quality of evidence is graded “Very Low” in both entries, meaning the conclusion is mechanistic rather than trial-proven[2].
The one real caveat is gastric emptying. Liverpool notes that semaglutide, oral and injectable, “delays gastric emptying and has the potential to impact the rate of absorption of concomitantly administered oral medicinal products,” and says the same of tirzepatide[2][3]. For the antiretrovirals actually studied, the answer is reassuring: “based on available interaction studies, a clinically relevant effect is not expected with emtricitabine or tenofovir alafenamide,” and likewise with bictegravir, emtricitabine, and tenofovir alafenamide[2][3]. One practical dosing rule does apply to oral semaglutide (Rybelsus): food, drink, and other oral medicines interfere with its absorption, so wait at least 30 minutes after taking it before any other oral medication[2]. Keeping viral-load monitoring on schedule is the sensible safeguard.
Why this question matters specifically for people living with HIV
Weight gain is a documented feature of modern ART. The federal guidelines state that weight gain occurs with nearly all regimens but is “most pronounced with integrase strand transfer inhibitors (INSTIs), especially bictegravir and dolutegravir, and the nucleotide reverse transcriptase inhibitor (NRTI) tenofovir alafenamide (TAF),” and that pooled data from eight randomized trials found about 13% of people with HIV gain more than 10% of body weight in the first year[1]. Populations with greater ART-associated gain include female sex, older age, Black race or African descent, and greater HIV disease severity[1].
The ADVANCE trial in South Africa quantified it at 96 weeks: men gained +1.2 kg on EFV/TDF/FTC, +3.5 kg on DTG/TDF/FTC, and +5.9 kg on DTG/TAF/FTC; women gained +3.4 kg, +5.3 kg, and +8.3 kg respectively — roughly 13 to 18 pounds for women on DTG/TAF/FTC[8]. Gains of 10% or more occurred in 51% of women and 42% of men on DTG/TAF/FTC[8]. NAMSAL in Cameroon reported the same dolutegravir weight signal at week 96[1]. None of this is a reason to stop an effective regimen — it is a reason to treat weight as part of HIV care.
Cardiometabolic stakes: the same pounds appear to cost more
The federal guidelines cite the Veterans Aging Cohort Study finding each 5-pound gain associated with a 14% greater diabetes risk in people with HIV versus 8% in people without HIV, and the D:A:D cohort showing an 18%–20% increased relative cardiovascular-disease risk per 1.0 kg/m² BMI increase among people with HIV who started ART at normal weight — versus 4%–5% per unit in a comparable Finnish cohort without HIV[1]. ACTG cohort data link greater than 10% weight gain within a year of starting ART to higher risk of type 2 diabetes, metabolic syndrome, and cardiometabolic events[1].
That elevated baseline risk is what REPRIEVE addressed on the lipid side. The NIH trial enrolled 7,769 people with HIV aged 40–75, more than 30% women, all on ART with low-to-moderate traditional CVD risk; daily pitavastatin 4 mg lowered major adverse cardiovascular events by 35% versus placebo, and the trial stopped early for efficacy[7]. Cardiometabolic care is now squarely part of HIV care.
What the HIV-specific GLP-1 evidence actually shows
The only randomized controlled trial to date in HIV enrolled 108 participants with HIV-associated lipohypertrophy and overweight or obese BMI, without diabetes, randomized to weekly subcutaneous semaglutide 1.0 mg or placebo for 24 weeks after an 8-week titration; estimated weight loss was 10.4%, with significant reductions in total body fat and abdominal visceral adipose tissue[1]. Published in Lancet Diabetes & Endocrinology in 2024, visceral fat fell 30.6%, subcutaneous abdominal fat 11.2%, and total body fat 18.9%; safety signals included one grade 4 elevated lipase and two cases of cholelithiasis[4]. Investigators flagged a trade-off: reductions in limb fat and lean mass raised concerns about worsening peripheral lipoatrophy[10].
ACTG A5371 (SLIM LIVER), presented at CROI 2024, gave semaglutide 1.0 mg weekly for 24 weeks to 49 adults with HIV and steatotic liver disease — 43% women, 33% Black, 39% Hispanic, 82% on an INSTI — with significant improvements in liver fat, weight (average 8.1%), A1C, ALT, and triglycerides; muscle volume decreased without a significant change in physical function[5][1]. A CNICS real-world cohort of 222 people with HIV on semaglutide found −6.47 kg and −1.07% A1C at one year, with equal weight loss whether or not they were on an INSTI[6].
Safety, monitoring, and the guideline position
The federal panel's position is deliberately measured: HIV studies showed an adverse-event profile similar to the general population, but the 1.0 mg dose used is lower than the maximum approved 2.0 mg (diabetes) and 2.4 mg (obesity) doses, so safety at higher doses or longer duration in people with HIV “are currently unknown.” Until more data exist, the Panel on Antiretroviral Guidelines for Adults and Adolescents “advises prescribing GLP-1 and GLP-1/GIP RAs among people with HIV based on current general population indications and prescribing information”[1].
Expected side effects are the class norms: nausea, vomiting, abdominal pain, constipation, and diarrhea, plus reported gallbladder and biliary events, rare acute kidney injury, and injection-site discomfort or erythema[9]. SLIM LIVER investigators note real benefit at the lower 1.0 mg dose, which may be more tolerable long-term and supports titrating to the lowest effective dose[11]; clinicians interviewed by TheBody describe a “go low and slow” approach[12].
Injection sites: nothing HIV-specific is documented. Redness or mild itchiness at the site is common[12]. Anyone with a low CD4 count should watch injection sites for signs of infection and report them promptly — a general immunosuppression precaution rather than a GLP-1-specific finding.
Muscle mass: because both HIV and GLP-1-driven weight loss can reduce lean mass, protein intake and resistance exercise deserve real attention alongside the medication[5].
What to ask your HIV provider
Bring three things to the appointment.
First, your current regimen by name. The interaction answer is strongest for BIC/FTC/TAF and FTC/TAF specifically, and your provider or pharmacist can check any other combination in the Liverpool checker at hiv-druginteractions.org[2]. Second, your reason for asking — diabetes, prediabetes, fatty liver, or weight — because indication drives both clinical choice and insurance approval[13]. Third, a monitoring plan: viral load on schedule, A1C and liver enzymes if relevant, and attention to muscle mass and nutrition[1][5]. Coordination between HIV care, primary care, and endocrinology is worth arranging up front rather than after a prior-authorization denial.
Florida: coverage, cost, and compounded semaglutide
Cost is the practical barrier — KFF puts GLP-1 list prices around $1,000 per month[13]. Coverage depends heavily on indication: Wegovy (approved for weight loss) is covered by just 1% of ACA Marketplace prescription drug plans, while Ozempic (same molecule, diabetes indication) is covered by 82% — and every Marketplace plan that covers an obesity-indicated GLP-1 requires prior authorization[13]. Florida uses the federally facilitated Marketplace, so that analysis maps directly onto the plans Floridians buy. Talking through indication with your provider is the single most useful step before a prior-authorization request.
Florida also has real stakes here: the state had the fifth-highest HIV-related death rate among U.S. jurisdictions in 2024, at 2.8 per 100,000[14] — one reason cardiometabolic care coordination matters locally.
Compounded semaglutide — status as of this page's review date. FDA states that tirzepatide and semaglutide “do not currently appear on the 503B bulks list or on FDA's drug shortage list,” which is the legal basis outsourcing facilities need[15]. Enforcement discretion for 503A pharmacies compounding semaglutide injection has ended, and it ended for 503B outsourcing facilities on May 22, 2025[15]. In an April 1, 2026 update, FDA reiterated that compounded products essentially copying a commercially available drug do not qualify for the 503A exemption — including semaglutide-plus-B12 combinations within 10% of approved strengths — while noting it does not currently intend to act against a compounder filling four or fewer such prescriptions per calendar month[15]. This policy has changed repeatedly; verify FDA's current statement before relying on it.
Related questions
Will a GLP-1 make my HIV medication stop working?
No clinically significant interaction is expected. GLP-1s are cleared by peptidases, not CYP450, and the Liverpool HIV drug-interaction database rates semaglutide with FTC/TAF and tirzepatide with BIC/FTC/TAF as “No Interaction Expected.” Keep your viral-load monitoring on schedule anyway.
Does it still work if my weight gain came from my ART?
Yes. In a real-world cohort of 222 people with HIV, weight loss at one year was essentially identical whether or not someone was on an integrase inhibitor: −6.49 kg versus −6.38 kg.
Should I be worried about losing muscle?
It's worth watching. The randomized HIV trial found reductions in limb fat and lean mass alongside visceral fat loss, raising lipoatrophy concerns, and SLIM LIVER saw decreased muscle volume without measurable loss of physical function. Discuss protein intake and resistance training with your care team.
Is compounded semaglutide from a telehealth service a safe shortcut?
It is legally and clinically riskier now than it was during the shortage. Semaglutide and tirzepatide are no longer on FDA's shortage list, enforcement discretion for compounded semaglutide injection has ended, and FDA treats most compounded copies of approved products as outside the compounding exemptions. Ask your provider about prior authorization on the FDA-approved product first.
Related from RiseUpToHIV
References & Sources
- Clinicalinfo.HIV.gov — Weight Gain in People With Treated HIV (Adult and Adolescent ARV Guidelines). Federal panel guidance on GLP-1/GIP receptor agonists, ART-associated weight gain, cardiometabolic risk, and HIV-specific trial summaries. ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩
- Liverpool HIV Drug Interactions — Semaglutide + FTC/TAF. Metabolism by neutral endopeptidase, “Very Low” evidence grading, gastric-emptying note, and the Rybelsus 30-minute dosing rule. ↩ ↩ ↩ ↩ ↩ ↩ ↩
- Liverpool HIV Drug Interactions — Tirzepatide + BIC/FTC/TAF. “No Interaction Expected” rating with Biktarvy components; metabolism by proteolytic cleavage. ↩ ↩ ↩ ↩ ↩
- Lancet Diabetes Endocrinol (2024) — Once-weekly semaglutide in people with HIV-associated lipohypertrophy. The randomized trial (108 participants, semaglutide 1.0 mg weekly): body-composition results and safety signals. ↩
- ACTG — CROI 2024: SLIM LIVER (A5371) results. Semaglutide 1.0 mg in 49 adults with HIV and steatotic liver disease; liver fat, weight, A1C, and muscle-volume findings. ↩ ↩ ↩
- CNICS cohort — Weight loss associated with semaglutide among people with HIV. Real-world one-year outcomes in 222 people with HIV, with and without INSTI use. ↩
- NIH — REPRIEVE: daily statin reduces cardiovascular risk in people with HIV. 7,769 participants; 35% reduction in major adverse cardiovascular events with pitavastatin. ↩
- aidsmap — ADVANCE 96-week weight-gain results. Kilogram gains by regimen and sex, and the share gaining 10% or more of body weight. ↩ ↩
- NIH StatPearls — Semaglutide. Approved doses and the documented adverse-effect profile. ↩ ↩
- HIV i-Base — Semaglutide in people with HIV: reduces central and peripheral fat. Reports the lipoatrophy concern from the randomized trial. (Note: i-Base lists 10 mg and 104 participants; the published trial and federal guidelines report 1.0 mg and 108 participants.) ↩
- University of Washington National HIV Curriculum — Semaglutide studies in people with HIV. Expert discussion of dosing to the lowest effective dose and tolerability. ↩
- TheBody — GLP-1s and HIV: What You Need to Know Before Starting. Community-voice reporting; clinicians' “go low and slow” framing and injection-site experience. ↩ ↩ ↩
- KFF — Costly GLP-1 drugs are rarely covered for weight loss by Marketplace plans. List prices near $1,000/month; Wegovy covered by 1% and Ozempic by 82% of Marketplace drug plans, with universal prior authorization for obesity indications. ↩ ↩ ↩
- CDC — HIV Diagnoses, Deaths, and Prevalence. Florida's 2024 HIV-related death rate of 2.8 per 100,000, fifth-highest among U.S. jurisdictions. ↩
- FDA — FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. Shortage-list status, end of enforcement discretion (503B on May 22, 2025), and the April 1, 2026 update on compounded copies. Re-verify before publication. ↩ ↩ ↩
Community publications like POZ, Positively Aware, and TheBody inform framing and lived-experience context on RiseUpToHIV. Every clinical, epidemiological, or public-health claim above is anchored to a primary source.